This is a summary of the European public assessment report (EPAR) for Lantus. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Lantus.
Therapeutic Indication
### Therapeutic indication Treatment of diabetes mellitus in adults, adolescents and children aged two years and above
Therapeutic Area (MeSH)
ATC Code
A10AE04
ATC Item
insulin glargine
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| insulin glargine | N/A | 甘精胰岛素 |
EMA Name
Lantus
Medicine Name
Lantus
Aliases
N/A
